| Title |
|
|
|
Dose painting in radiotherapy for head and neck squamous cell carcinoma : value of repeated functional imaging with PET, -fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| The purpose of this work was to evaluate the potential of functional imaging with 18F-FDG PET, 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI to provide an appropriate and reliable biologic target for dose painting in radiotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Fifteen patients with locally advanced HNSCC, treated with concomitant chemoradiotherapy, were prospectively enrolled in a bioimaging protocol. Sequential PET (18F-FDG and 18F-fluoromisonidazole) and MRI (T1, T2, dynamic enhanced, and diffusion-weighted sequences) were performed before, during, and after radiotherapy. Results: Median follow-up was 30.7 mo (range, 6.356.3 mo); in 7 patients, disease recurred. Disease-free survival correlated negatively with the maximum tissue-to-blood 18F-fluoromisonidazole ratio (T/Bmax) on the baseline 18F-fluoromisonidazole scan (P = 0.04), with the size of the initial hypoxic volume (P = 0.04), and with T/Bmax on the 18F-fluoromisonidazole scan during treatment (P = 0.02). All locoregional recurrences were within the 18F-FDGavid regions on baseline 18F-FDG PET; 3 recurrences mapped outside the hypoxic volume on baseline 18F-fluoromisonidazole PET. Lesions (primary tumor and lymph nodes) where a locoregional recurrence developed during follow-up had significantly lower apparent diffusion coefficients on diffusion-weighted MRI during week 4 of radiotherapy (0.0013 vs. 0.0018 mm2/s, P = 0.01) and at 3 wk after treatment (0.0014 vs. 0.0018 mm2/s, P = 0.01) and a significantly higher initial slope on baseline dynamic enhanced MRI (26.2 vs. 17.5/s, P = 0.03) than did lesions that remained controlled. Conclusion: These results confirm the added value of 18F-FDG PET and 18F-fluoromisonidazole PET for radiotherapy planning of HNSCC and suggest the potential of diffusion-weighted and dynamic enhanced MRI for dose painting and early response assessment. | | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
The Journal of nuclear medicine. - New York | |
| Publication |
|
|
|
New York : 2009
| |
| ISSN |
|
|
|
0161-5505
| |
| Volume/pages |
|
|
|
50:7(2009), p. 1020-1027
| |
| ISI |
|
|
|
000272547100010
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (publisher's version - intranet only) |
|
|
| | |
|